The Primary Question for LCT is "what is the plan after May 2018?"
My belief is that the data will provide and strong indication that the LCT Treatment NTcell may well halt the progression of Parkinson Disease.
The fundamental question is how will LCT commercialise this Technology, where are the dollars generated?, when will the dollars be generated? and How Much ?
Will any Royalties be paid to LCT from Diabecell in the immediate future? what happens to DOL if LCT cannot continue?
LCT as a company don't seemed to have learnt a thing about Shareholder updates, Market Updates and Paid Investor Content. They have effectively now held the shareholders investment funds for 12 years with no income or revenue from products or services? and have no business plan involving return of investment that the SH are aware of?
as Whytee says , we can Only But Wait and See.
- Forums
- ASX - By Stock
- Hold , Wait and See
The Primary Question for LCT is "what is the plan after May...
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AI (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $36.63K | 5.233M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 8402318 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 5168675 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 8402318 | 0.006 |
13 | 5943716 | 0.005 |
5 | 3095009 | 0.004 |
3 | 3800000 | 0.003 |
2 | 1050000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 5168675 | 7 |
0.009 | 1589992 | 7 |
0.010 | 2413365 | 3 |
0.011 | 90000 | 1 |
0.012 | 1038160 | 4 |
Last trade - 14.26pm 11/11/2024 (20 minute delay) ? |
Featured News
1AI (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online